查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604747

自闭症频谱市场：按产品类型、药物、分销划分 - 全球预测 2025-2030

Autism Spectrum Disorders Market by Product Type (Aripiprazole, Balovaptan, Bumetanide), Drug (Anticonvulsants, Antipsychotics, Selective Serotonin Reuptake Inhibitors), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

自闭症频谱市场2023年估值为5.4426亿美元，预计到2024年将达到5.7718亿美元，复合年增长率为6.14%，预计到2030年将达到8.2612亿美元。

自闭症频谱(ASD) 涵盖一系列神经发育障碍，其特征是社交互动、沟通和重复行为的挑战。自闭症谱系障碍盛行率不断上升，每44 名确诊患者中就有1 人受到自闭症谱系障碍的影响，这凸显了对治疗、教育和支持干预措施的迫切需要，因此需要更深入地了解自闭症谱系障碍。应用范围包括医疗诊断、製药、行为治疗和专业教育工具，最终用途包括医院、学校、研究机构和復健中心。关键的成长要素包括早期诊断意识的提高、诊断方法的技术进步以及政府资助的增加。例如，利用人工智慧进行早期检测和个人化治疗计划显示出巨大的潜力。最近的商机在于远端医疗平台，该平台促进远距评估和治疗会议，提供便利和广泛的覆盖范围。然而，治疗成本上升、缺乏训练有素的专业人员以及获得优质治疗的社会经济障碍阻碍了市场成长。文化偏见和监管挑战也使这些问题变得复杂，限制了更广泛的接受和实施。技术创新的机会倾向于开发具有成本效益的诊断工具、增强数位疗法以及利用基因组研究来更好地了解自闭症谱系障碍的病因和多样性。透过以适应性强、低成本的产品进入新兴市场，公司可以吸引服务不足的人。由于市场竞争激烈且分散，主要企业都专注于内部成长和收购主导的成长策略，以扩大其产品范围。公司应与研究机构建立策略伙伴关係，以维持创新曲线的领先地位，并考虑与非营利组织建立伙伴关係，以加强社区推广和支援服务。未来，个人化医疗和整合多种治疗方法的整体方法的创新可能成为竞争前沿，为自闭症谱系障碍患者提供更全面的解决方案。

主要市场统计
基准年[2023] 5.4426亿美元
预计年份 [2024] 57718万美元
预测年份 [2030] 8.2612亿美元
复合年增长率（%） 6.14%

市场动态：揭示快速发展的自闭症频谱市场的关键市场洞察

自闭症频谱市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • ASD 患者增加
    • 增加政府资助的自闭症意识项目
    • 改善自闭症筛检和诊断
  • 市场限制因素
    • 关于产品核可的严格规定
  • 市场机会
    • 加大研发治疗自闭症谱系障碍的有效药物
    • 临床试验中新的自闭症治疗方法的出现
  • 市场挑战
    • 缺乏诊断自闭症的专家

波特五力：驾驭自闭症频谱市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解自闭症频谱市场的外部影响

外部宏观环境因素在塑造自闭症频谱市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解自闭症频谱市场的竞争格局

自闭症频谱市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵自闭症频谱市场供应商绩效评估

FPNV定位矩阵是评估自闭症频谱市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製自闭症频谱市场的成功之路

自闭症频谱市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自闭症频谱(ASD) 患者盛行率不断增加
      • 增加政府资助的自闭症意识项目
      • 改善自闭症筛检和诊断
    • 抑制因素
      • 关于产品核可的严格规定
    • 机会
      • 扩大 ASD 治疗有效药物的研发活动
      • 临床试验中新的自闭症治疗方法的出现
    • 任务
      • 缺乏诊断自闭症的专家
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自闭症频谱市场：依产品类型

  • Aripiprazole
  • Balovaptan
  • Bumetanide
  • CM-AT
  • 褪黑素
  • Risperidone

第七章自闭症频谱药物市场

  • 抗惊厥药
  • 抗精神病药
  • 选择性血清素再回收抑制剂

第八章 自闭症频谱市场经销商

  • 医院
  • 零售药房

第九章美洲自闭症频谱市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区自闭症频谱市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲自闭症频谱市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Curemark, LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Hopebridge, LLC
  • Intra-Cellular Therapies, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Neurim Pharmaceuticals Ltd.
  • Novartis AG
Product Code: MRR-436901065E81

The Autism Spectrum Disorders Market was valued at USD 544.26 million in 2023, expected to reach USD 577.18 million in 2024, and is projected to grow at a CAGR of 6.14%, to USD 826.12 million by 2030.

Autism Spectrum Disorders (ASD) encompass a range of neurodevelopmental conditions characterized by challenges in social interaction, communication, and repetitive behaviors. The necessity for a deep understanding of ASD arises from its increasing prevalence, with one in every 44 children diagnosed, highlighting urgent needs in therapeutic, educational, and supportive interventions. Applications span across healthcare diagnostics, pharmaceuticals, behavioral therapy, and specialized educational tools, while the end-use scope includes hospitals, schools, research institutions, and rehabilitation centers. Key growth factors include rising awareness about early diagnosis, technological advancements in diagnostic methodologies, and increased governmental funding. For instance, the use of Artificial Intelligence for early detection and personalized treatment plans has showcased significant potential. Recent opportunities lie in telehealth platforms which facilitate remote assessments and therapy sessions, offering convenience and broader reach. However, market growth is hampered by high costs of treatment, scarcity of trained professionals, and socio-economic barriers in accessing quality care. Cultural stigma and regulatory challenges further compound these issues, limiting broader acceptance and implementation. Opportunities for innovation lean towards developing cost-effective diagnostic tools, enhancing digital therapeutics, and leveraging genomic research to better understand ASD etiology and variance. Entering emerging markets with adaptable, low-cost products can enable firms to capture underserved demographics. The nature of the market is competitive and fragmented, with key players focused on both organic and acquisition-led growth strategies to expand their offerings. Companies should form strategic partnerships with research institutions to stay ahead in the innovation curve and consider collaborations with non-profits to enhance community outreach and support services. Moving forward, innovation in personalized medicine and holistic approaches integrating multiple therapies could define the competitive frontier, enabling more inclusive solutions for individuals with ASD.

KEY MARKET STATISTICS
Base Year [2023] USD 544.26 million
Estimated Year [2024] USD 577.18 million
Forecast Year [2030] USD 826.12 million
CAGR (%) 6.14%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autism Spectrum Disorders Market

The Autism Spectrum Disorders Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of patients with autism spectrum disorders (ASD)
    • Rise in government-sponsored awareness programs for autism
    • Improvements in autism screening and diagnostics
  • Market Restraints
    • Stringent regulations on product approval
  • Market Opportunities
    • Growing research & development activities for effective drugs for the treatment of ASD
    • Emergence of new autism medications undergoing clinical trials
  • Market Challenges
    • Lack of autism specialists to diagnose the disorder

Porter's Five Forces: A Strategic Tool for Navigating the Autism Spectrum Disorders Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autism Spectrum Disorders Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autism Spectrum Disorders Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autism Spectrum Disorders Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autism Spectrum Disorders Market

A detailed market share analysis in the Autism Spectrum Disorders Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autism Spectrum Disorders Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autism Spectrum Disorders Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autism Spectrum Disorders Market

A strategic analysis of the Autism Spectrum Disorders Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autism Spectrum Disorders Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Curemark, LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Hopebridge, LLC, Intra-Cellular Therapies, Inc., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V., Neurim Pharmaceuticals Ltd., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Autism Spectrum Disorders Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Aripiprazole, Balovaptan, Bumetanide, CM-AT, Melatonin, and Risperidone.
  • Based on Drug, market is studied across Anticonvulsants, Antipsychotics, and Selective Serotonin Reuptake Inhibitors.
  • Based on Distribution, market is studied across Hospitals and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of patients with autism spectrum disorders (ASD)
      • 5.1.1.2. Rise in government-sponsored awareness programs for autism
      • 5.1.1.3. Improvements in autism screening and diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations on product approval
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities for effective drugs for the treatment of ASD
      • 5.1.3.2. Emergence of new autism medications undergoing clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of autism specialists to diagnose the disorder
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autism Spectrum Disorders Market, by Product Type

  • 6.1. Introduction
  • 6.2. Aripiprazole
  • 6.3. Balovaptan
  • 6.4. Bumetanide
  • 6.5. CM-AT
  • 6.6. Melatonin
  • 6.7. Risperidone

7. Autism Spectrum Disorders Market, by Drug

  • 7.1. Introduction
  • 7.2. Anticonvulsants
  • 7.3. Antipsychotics
  • 7.4. Selective Serotonin Reuptake Inhibitors

8. Autism Spectrum Disorders Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Retail Pharmacies

9. Americas Autism Spectrum Disorders Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autism Spectrum Disorders Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autism Spectrum Disorders Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Bristol-Myers Squibb Company
  • 4. Curemark, LLC
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Hopebridge, LLC
  • 8. Intra-Cellular Therapies, Inc.
  • 9. Jazz Pharmaceuticals, Inc.
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Neurim Pharmaceuticals Ltd.
  • 14. Novartis AG

LIST OF FIGURES

  • FIGURE 1. AUTISM SPECTRUM DISORDERS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTISM SPECTRUM DISORDERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTISM SPECTRUM DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTISM SPECTRUM DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTISM SPECTRUM DISORDERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTISM SPECTRUM DISORDERS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY BALOVAPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY BUMETANIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY CM-AT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY MELATONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 148. AUTISM SPECTRUM DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. AUTISM SPECTRUM DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023